Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial.

Abstract

UNLABELLED:

Meningiomas express members of the somatostatin receptor family. The present study assessed the long-term benefits and harm of somatostatin-based radiopeptide therapy in meningioma patients.

METHODS:

Patients with progressive unresectable meningioma were treated with (90)Y-DOTATOC and (177)Lu-DOTATOC until tumor progression or permanent toxicity occurred. Multivariable Cox regression analyses were used to study predictors of survival.

RESULTS:

Overall, 74 treatment cycles were performed on 34 patients. Stable disease was achieved in 23 patients. Severe hematotoxicity occurred in 3 patients, and severe renal toxicity in 1 patient. Mean survival was 8.6 y from the time of recruitment. Stable disease after treatment (hazard ratio, 0.017 vs. progressive disease; 95% confidence interval, 0.001-0.35; n = 34; P = 0.01) and high tumor uptake (hazard ratio, 0.046 vs. intermediate or low tumor uptake; 95% confidence interval, 0.004-0.63; n = 34; P = 0.019) were associated with longer survival.

CONCLUSION:

(90)Y-DOTATOC and (177)Lu-DOTATOC are promising tools for treating progressive unresectable meningioma, especially in cases of high tracer uptake in the tumor.

• Authors: Nicolas Marincek, Piotr Radojewski, Rebecca A Dumont, Philippe Brunner, Jan Müller-Brand, Helmut R Maecke, Matthias Briel, Martin A Walter
• Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine (J Nucl Med) Vol. 56 Issue 2 Pg. 171-6 (Feb 2015) ISSN: 1535-5667 [Electronic] United States
• PMID: 25593116 (Publication Type: Clinical Trial, Phase II, Journal Article)
• Copyright: © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Chemical References

• 177Lu-octreotide, DOTA(0)-Tyr(3)-
• Radiopharmaceuticals
• Receptors, Somatostatin
• 90Y-octreotide, DOTA-Tyr(3)-
• Octreotide

Topics

• Adult
• Aged
• Aged, 80 and over
• Central Nervous System Neoplasms (mortality, radiotherapy)
• Disease Progression
• Female
• Humans
• Kaplan-Meier Estimate
• Male
• Meningioma (mortality, radiotherapy)
• Middle Aged
• Octreotide (analogs & derivatives, chemistry)
• Proportional Hazards Models
• Prospective Studies
• Radiopharmaceuticals (therapeutic use)
• Receptors, Somatostatin (chemistry)
• Treatment Outcome